InsidersTradesSigma
Follow the Sonnet BioTherapeutics Holdings, Inc. stock price and the full management transaction log of the company, a publicly traded company based in United States. Shares are quoted on the US market, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, Sonnet BioTherapeutics Holdings, Inc. has logged 64 public disclosures. The latest transaction was disclosed on 4 December 2025 (Disposition). Among the most active insiders: Dexter Susan. The full history is free.
64
Insider Decl.
n/a
Thresholds
€167,643
10 ops.
Buy Volume
n/a
13 ops.
Sell Volume
30Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 4 December 2025
Declarations64 total
9,374 sharesCommon StockSEC:0001493152-25-026217:0
10,375 sharesCommon StockSEC:0001493152-25-026063:0
6,446 sharesCommon StockSEC:0001493152-25-026069:0
9,643 sharesCommon StockSEC:0001493152-25-026068:0
10,547 sharesCommon StockSEC:0001493152-25-026066:0
4,394 sharesCommon StockSEC:0001493152-25-026065:0
14,116 sharesCommon StockSEC:0001493152-25-026064:0
4,537 sharesCommon StockSEC:0001493152-25-026062:0
4,000 sharesCommon StockSEC:0001641172-25-019785:0
10,000 sharesCommon StockSEC:0001641172-25-019777:0
12,000 sharesCommon StockSEC:0001641172-25-019778:0
4,000 sharesCommon StockSEC:0001641172-25-019783:0
6,000 sharesCommon StockSEC:0001641172-25-019782:0
8,000 sharesCommon StockSEC:0001641172-25-019781:0
10,000 sharesCommon StockSEC:0001641172-25-019780:0
8,000 sharesCommon StockSEC:0001641172-25-019779:0
1,888 sharesCommon StockSEC:0001493152-24-048952:0
1,452 sharesCommon StockSEC:0001493152-24-048950:0
7,554 sharesCommon StockSEC:0001493152-24-048951:0
373 sharesCommon StockSEC:0001493152-24-048956:0
1,452 sharesCommon StockSEC:0001493152-24-048958:0
1,271 sharesCommon StockSEC:0001493152-24-048953:0
373 sharesCommon StockSEC:0001493152-24-048957:0
25 of 64 declarations
关于 Sonnet BioTherapeutics Holdings, Inc.
Sonnet BioTherapeutics Holdings, Inc. 是一家总部位于美国的生物技术公司，在纳斯达克上市，股票代码为 SONN。该公司的运营总部位于新泽西州普林斯顿，其公司足迹集中在美国。Sonnet 最好的描述是临床阶段肿瘤生物技术平台公司，而非商业药物制造商。其核心技术是专有的 FHAB (Fully Human Albumin Binding) 平台，旨在改善生物药物（包括单功能和双功能构建体）的药代动力学、组织靶向和治疗特性。([sonnetbio.com](https://www.sonnetbio.com/investors/news-events/press-releases/detail/132/sonnet-biotherapeutics-holdings-inc-announces-stockholder?utm_source=openai)) Sonnet 成立于 2011 年，围绕靶向生物制剂和免疫治疗导向项目开发了其产品线。该公司曾重点介绍过多个临床前和临床阶段资产，包括 SON-1010、SON-1210、SON-1400、SON-1411 和 SON-080。这种广度反映了平台战略：该公司试图利用相同的底层技术在肿瘤学和相邻治疗领域生成多种候选药物。截至此处披露的最新公开信息，Sonnet 仍是一家处于开发阶段的公司，没有上市产品，这意味着投资案例主要基于临床执行、知识产权实力和战略合作潜力。([sonnetbio.com](https://www.sonnetbio.com/news-media/press-releases/detail/59/sonnet-biotherapeutics-announces-successful-completion-of?utm_source=openai)) 从竞争角度来看，Sonnet 在一个高度拥挤的市场中运营，该市场由大型制药公司和众多肿瘤学和免疫学生物技术公司主导。其差异化因素是 FHAB 平台，该公司表示该平台可以支持灵活的有效载荷设计，并可能创建协同的生物组合。该公司还强调在美国和欧洲的专利保护，这在排他性和产品线差异化对估值至关重要的行业中非常重要。对于投资者而言，这使得 SONN 成为一个高风险、高回报的生物技术故事，而非成熟的医疗保健特许经营权。([sonnetbio.com](https://www.sonnetbio.com/investors/news-events/press-releases/detail/32/sonnet-biotherapeutics-announces-issuance-of-u-s-patent?utm_source=openai)) 公司近期发展包括持续传达平台扩展、对抗体-药物偶联物合作机会的兴趣，以及与 Hyperliquid Strategies Inc. 的股东批准的业务合并。该交易是一个重大的战略事件，可能会影响市场未来对公司的估值。总的来说，Sonnet 的近期历史表明该公司正处于转型期，临床数据、许可机会和公司行动可能比近期运营收入更重要。([sonnetbio.com](https://www.sonnetbio.com/news-media/press-releases/detail/117/sonnet-biotherapeutics-announces-that-its-proprietary?utm_source=openai))
